DxS is a personalised medicine company providing cancer mutation products, technologies and genetic analysis services to enable the delivery of safe and effective medicines. The speed and sensitivity of DxS’ real-time PCR technology, Scorpions, underpins its products and services. This class-leading technology is also available for licence to diagnostic companies and for research, applied and other applications. DxS has developed a range of tumour analysis products that detect mutations in EGFR, RAS, RAF and other genes associated with cancer drug responses.
DxS is ISO9001:2000 certified for the provision of genetic and related analytical and development services and technology licensing for life sciences. DxS is an established company operating in Manchester’s technology quarter within the UK.
Corporate | Cancer Mutation Products | Molecular Diagnostic Technologies | Genetic Analysis Services
Contact Us | Home